Aptamer Group (LSE:APTA) Debt-to-Revenue : 1.77 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptamer Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.41 Mil. Aptamer Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.64 Mil. Aptamer Group's annualized Revenue for the quarter that ended in Dec. 2023 was £0.60 Mil. Aptamer Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.77.

Aptamer Group Debt-to-Revenue Historical Data

The historical data trend for Aptamer Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Debt-to-Revenue Chart

Aptamer Group Annual Data

Trend

Mar19

Mar20

Jun22

Jun23

Debt-to-Revenue

0.07

0.19

0.32

0.62

Aptamer Group Semi-Annual Data
	Mar19	Mar20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial			0.07	0.25	0.18	0.73	1.77

Competitive Comparison of Aptamer Group's Debt-to-Revenue

For the Biotechnology subindustry, Aptamer Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptamer Group's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptamer Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptamer Group's Debt-to-Revenue falls into.

Aptamer Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptamer Group's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.314	+	0.764)	/	1.752
	=	0.62

Aptamer Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.412	+	0.644)	/	0.596
	=	1.77

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Aptamer Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptamer Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptamer Group (LSE:APTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Innovation Way, Windmill House, York, GBR, YO10 5BR

Website

https://www.aptamergroup.com

Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines